Merck & Co. shares are in focus Monday after a wave of analyst activity capped by a new FDA approval for its cancer drug Keytruda.
Merck & Co. Inc. (NYSE:MRK) shares are in focus Monday after a wave of analyst activity capped by a new FDA approval for its cancer drug Keytruda.
Merck stock is trading near recent highs. What’s the outlook for MRK shares?
Analyst Consensus and Recent Actions The stock carries a Buy rating with an average price target of $133.86. Recent analyst moves include:
Morgan Stanley: Equal-Weight (Raises Target to $113.00) (July 9)
RBC Capital: Outperform (Maintains Target to $142.00) (July 8)
Wall St analysts changed outlook on top names. KBW cut AON PT to $400, Barclay's cut T PT to $24, MS cut ROL PT to $65, GS cut…
The pharmaceutical giant is a standout performer within the health-care sector, and the stock could be poised for a big jump.
Merck narrowed its 2026 sales guidance and hiked its adjusted profit outlook.
Moderna reports five-year melanoma trial results with Merck and expands its Ebola vaccine partnership with CEPI, but MRNA stock…
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find…
Merck will report its earnings on Tuesday, offering insights into how its agreement to lower the price of its diabetes drug has…
